SynAct Pharma
Change in number of shares and votes in SynAct Pharma AB
SynAct Pharma AB (the "Company") announces that the number of shares and votes has increased by 1,004,100 as a result of conversion of warrants, which was carried out in August 2025.
Today, the last trading day of the month, the total number of shares and votes in the Company amounts to 53,330,243. The conversion of 1 million warrants in August generated a total of 1,004,100 new shares, providing the company with SEK 17.7 million.
For further information, please contact:
Björn Westberg, CFO SynAct Pharma Tel: +46 733 940 953
Email: investor.relations@synactpharma.com
About SynAct Pharma AB
SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.
| Datum | 2025-08-29, kl 18:00 |
| Källa | MFN |
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!